ENDPOINTS

European regulator rejects Lilly's Alzheimer’s drug over side effects

Eli Lilly’s Alzheimer’s drug Kisunla has failed to get support from the European Medicines Agency over serious side effects and three patient deaths. The agency’s human medicines committee (CHMP) recommended that ...

Mar 28, 2025 - 14:50
 0
European regulator rejects Lilly's Alzheimer’s drug over side effects
Eli Lilly’s Alzheimer’s drug Kisunla has failed to get support from the European Medicines Agency over serious side effects and three patient deaths. The agency’s human medicines committee (CHMP) recommended that ...
Read More

Tags:

Previous Article

The First Sightings of Hofstadter's Butterfly Emerged from a Happy Accident

Next Article

Detecting Exoplanets by their Magnetospheres

Related Posts

Indian drugmakers join forces to boost national biomanufacturing sector  

Indian drugmakers join forces to boost national biomanu...

Feb 25, 2025  0

Denali stops some work on ALS drug after analysis showed no impact on key biomarker

Denali stops some work on ALS drug after analysis showe...

Mar 6, 2025  0

Thermo Fisher buys Solventum's purification business for $4.1B

Thermo Fisher buys Solventum's purification business fo...

Feb 25, 2025  0